Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of LY4355756 in Healthy Participants
NCT07765498Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2026
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
Phase 1, randomised trial of LY4355756 (5 arms), sponsored by Eli Lilly and Company. Primary endpoints: Serious Adverse Events at 6 months and Treatment-Emergent Adverse Events at 6 months. Started Aug 2026; status: recruiting.
02
Drugs
LY4355756
Beyond the preview
Go deeper on NCT07765498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07765498.